We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Continuous therapy with lenalidomide in multiple myeloma.
- Authors
Bahlis, Nizar
- Abstract
In multiple myeloma, the depth and maintenance of response to therapy has been shown to correlate with improved survival. Therefore, treatment of residual disease after induction therapy may eradicate residual clonal plasma cells, sustain and/or deepen response and yield better outcomes. This article reviews 3 recent trials published in the New England Journal of Medicine investigating continuous therapy with lenalidomide. These trials each demonstrated improved outcomes for transplant- eligible and -ineligible patients treated with lenalidomide compared with placebo. While there was an increase in the rate of second primary malignancies (SPM), in an event-free survival analysis, the risk of progressive disease or death from myeloma outweighed the risk of SPM. Based on these data, continuous therapy with lenalidomide represents a new paradigm for the management of multiple myeloma patients.
- Subjects
CLINICAL trials; MULTIPLE myeloma treatment; TREATMENT effectiveness; DRUG efficacy; PLACEBOS
- Publication
Oncology Exchange, 2013, Vol 12, Issue 1, p20
- ISSN
1705-2394
- Publication type
Article